Format

Send to

Choose Destination
See comment in PubMed Commons below
Cytokine. 2010 Jul;51(1):25-7. doi: 10.1016/j.cyto.2010.04.006. Epub 2010 May 6.

Genetic variation in the visfatin (PBEF1/NAMPT) gene and type 2 diabetes in the Greek population.

Author information

1
Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupoli 68 100, Greece. ppaschou@mbg.duth.gr

Abstract

Visfatin (NAMPT formerly known as PBEF1) is an adipokine that is strongly expressed in visceral fat and has caused much debate among researchers, regarding its involvement in glucose homeostasis and insulin resistance. It was initially isolated from bone marrow cells, and its involvement in inflammatory procedures such as sepsis and acute lung inflammation is now evident. Several studies have also reported an association of plasma visfatin levels with obesity. We undertook an evaluation of the involvement of the NAMPT gene in the development of type 2 diabetes (T2DM) in the Greek population. We studied 178 patients with T2DM and 177 controls that were matched for sex, age and body mass index. We genotyped three tagging SNPs selected from the HapMap II CEPH European population as reference for the Greek population. These three SNPs tag another 12 SNPs over the entire NAMPT gene with a mean r(2) of 0.92. No indications of association with disease status were found with any of the tested variants or the inferred haplotypes. Results were also negative when the quantitative traits of weight and BMI were tested. Although our study covers common variants across the NAMPT gene, the possible involvement of rare variants in T2DM etiology cannot be ruled out and will require the investigation of very large numbers of cases and controls.

PMID:
20451405
DOI:
10.1016/j.cyto.2010.04.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center